Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00900302
Official study title

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Study summary

RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protein expression in the sentinel lymph nodes of patients with cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedprotein expression analysis and immunohistochemistry staining method

Plus 2 other study approaches.

Who it may be forCancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 10, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?OHSU Knight Cancer Institute

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
OHSU Knight Cancer Institute
Interventions being studied
Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • DISEASE CHARACTERISTICS:
  • Histologically or cytologically confirmed cancer, including, but not limited to, the following:
  • Melanoma
  • Breast cancer
  • Invasive squamous cell cancer
  • Other cancers for which patients underwent or will undergo the following:
  • Adequate archived paraffin-embedded tissue for making slides for immunostaining
  • Adequate freshly removed sentinel lymph node (and primary tumor, if available) tissue for laboratory assays
  • Clinical data and date of last follow-up on tumor stage and status must be available
  • Hormone receptor status not specified PATIENT CHARACTERISTICS:
  • Not specified PRIOR CONCURRENT THERAPY:
  • Not specified

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • OHSU Knight Cancer InstitutePortland, Oregon

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 10, 2016. Always confirm current availability with the study team.

View original record ↗